ArticleMolecular therapy. Methods & clinical development2025

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma.

Hui-Ju Hsieh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.